Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

https://newsroom.astellas.us/2019-03-28-Astellas-Five-Consecutive-Years-of-Perfect-Equality-Scores

Astellas: Five Consecutive Years of Perfect Equality Scores Read More

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia

Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Read More

Diversity & Inclusion

Diversity & Inclusion at Astellas

Hear from our employees about the importance of Diversity & Inclusion

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

1

2

3

4

News

Latest

News / Media

Apr 25, 2019

Changes of Representative Director and Directors

News / Media

Apr 25, 2019

Changes of Representative Director and Directors

News / Media

Apr 25, 2019

Astellas Announces Cancellation of Treasury Shares

News / Corporate

May 20, 2019

Astellas Oncology Announces C³ Prize® Call for Entries to Award $200,000 to the Best Ideas in Cancer Care Beyond Medicine

News / Corporate Awards

May 09, 2019

Astellas' Chelsea Glinski Named a 2019 Healthcare Businesswomen's Association Luminary

News / Corporate

May 05, 2019

New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin